Semaglutide-d8tetraTFA is a deuterium-labeled form of Semaglutide. Semaglutide is a long-acting, selective, competitive GLP-1 receptor agonist that crosses the blood-brain barrier. Upon activating the GLP-1 receptor, it enhances insulin secretion, suppresses gastric emptying and appetite, and improves mitochondrial function and lipid metabolism (such as reducing hepatic de novo lipogenesis). It offers antihyperglycemic, weight-reduction, neuroprotective (such as improving motor function in Parkinson's disease models and reducing α-synuclein aggregation), and hepatosteatosis amelioration effects. It is applicable in research on type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), and certain neurodegenerative and liver diseases, as well as cancer.